ArticleThe oncologist2026
Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFirst-line treatment of HER2-positive advanced gastric/GEJ adenocarcinoma now includes pembrolizumab added to trastuzumab plus chemotherapy (KEYNOTE-811). Zanidatamab, a bispecific anti-HER2 antibody, improved outcomes in HERIZON-GEA-01 but has not been directly compared with this standard.
methodsWe searched PubMed, Scopus, and the ASCO/ESMO libraries for phase II/III trials of previously untreated HER2-positive metastatic gastric/GEJ adenocarcinoma. Individual patient data were reconstructed from published Kaplan-Meier curves. Cox frailty models estimated hazard ratios using the pembrolizumab regimen as the reference. Restricted mean survival time analysis was performed at 12, 24, and 36 months.
resultsNine trials were included: trastuzumab + chemotherapy (n = 1466), pembrolizumab + trastuzumab + chemotherapy (n = 430), zanidatamab + chemotherapy (n = 350), and zanidatamab + tislelizumab + chemotherapy (n = 335). Median PFS was 12.5 months with both zanidatamab regimens vs 10.0 months with pembrolizumab. The zanidatamab-tislelizumab triplet significantly reduced progression hazard (HR, 0.78, 95% CI, 0.62-0.99; P = 0.042). Median OS was 27.0 and 25.3 months with zanidatamab arms vs 20.3 months with pembrolizumab. Both zanidatamab arms showed significantly longer OS at 36 months by RMST.
conclusionsZanidatamab-based regimens were associated with longer PFS and OS than the pembrolizumab standard, though direct randomized comparisons are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.